Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that an 8-week low-starch/low-dairy diet led to weight loss, improved insulin sensitivity, and reduced testosterone levels in women with PCOS.

This article discusses the principles and considerations of clinical photography for hair disorders in dermatology, reporting no new clinical findings.

In this study, serum PSA levels were higher in women with PCOS, suggesting it may serve as a marker for hyperandrogenism in this condition.

In this study, the authors concluded that clinical hyperandrogenism is not a reliable predictor for biochemical hyperandrogenism in Thai women with PCOS.

This study found that transgender men using testosterone therapy had higher rates of acne and increased body hair growth, resembling male patterns more closely than those not on testosterone.

In this study, spironolactone and spironolactone plus metformin both significantly reduced hirsutism scores in women with PCOS, but the combination therapy was not more effective than spironolactone alone regarding BMI, hormone levels, or insulin resistance.

This study found that a cream containing 6.0% Stryphnodendron adstringens bark extract effectively reduced terminal hair growth and improved skin conditions in women with excessive terminal hair.

This study found that finasteride treatment significantly reduced hirsutism and dihydrotestosterone levels in women with idiopathic hirsutism or polycystic ovary syndrome over six months.

This study found that hirsutism is more prevalent in Chinese women with PCOS compared to the general population, and the Ferriman-Gallwey score is a good predictor for diagnosing PCOS in this group.

This study concluded that the modified Ferriman-Gallwey score was more effective in detecting hyperandrogenism in PCOS patients compared to serum testosterone and free androgen index in Sri Lankan women.

This study concluded that PCOS patients, regardless of weight, have significantly lower serum amylin levels than healthy BMI-matched controls, while serum preptin levels did not vary significantly between groups.

This review discusses the causes and management of hirsutism and suggests improvement can be achieved with a combination of hair removal, suppression of androgen production, and lifestyle changes over 6 to 9 months.

This study found that finasteride gel 0.25% significantly decreased hair growth in women with idiopathic hirsutism over six months without any reported side effects.

This study found that both spironolactone with Ovysmen and cyproterone acetate with ethinyloestradiol significantly reduced hair growth in hirsute women, with no difference in effect between treatments.

In this study, the authors reported that depression and anxiety are more prevalent in patients with polycystic ovary syndrome compared to healthy women, reinforcing the need for routine mental health screening in this population.

This article discusses the diagnosis and treatment options for hirsutism and reports no new clinical findings.

This study found that serum androgen levels were associated with the severity of hirsutism in women, with significantly higher levels observed in those with moderate to severe hair growth.

This review discusses therapeutic principles for managing hirsutism and androgenetic alopecia during the menopausal transition and peri-/postmenopause but reports no new clinical results.

This review discusses the causes and treatment options for idiopathic hirsutism and reports that various therapies may reduce hirsutism severity and the Ferriman–Gallwey score by 35–40% after one year.

This study found that canrenone significantly reduced hair growth and decreased certain androgen levels in women with idiopathic post-puberal hirsutism, suggesting potential effectiveness as a treatment.

This study observed that over two-thirds of women with hirsutism experienced a moderate decline in quality of life, with severity of hirsutism linked to greater impact.

This case report describes a 64-year-old postmenopausal woman with hirsutism due to a rare case of bilateral diffuse ovarian Leydig cell hyperplasia, leading to normalized testosterone levels and improved glycaemic control following surgery.

This study demonstrated a significant association between high lipid accumulation product (LAP) and hirsutism in women with polycystic ovary syndrome (PCOS).

This review discusses androgenization symptoms like hirsutism, alopecia, and acne in reproductive-age women, focusing on diagnostic and therapeutic approaches, and highlights postmenopausal considerations, but presents no new clinical findings.

In this study of women with PCOS in a rural setting, researchers observed no significant differences in hormonal or metabolic profiles based on age at menarche, but early menarche was associated with higher hirsutism, suggesting it could serve as an indicator of hyperandrogenism risk.

This study found that 10.3% of female high school students in Islamabad screened positive for PCOS, with associations including irregular menstrual cycles and higher BMI among those testing positive.

This study highlights that hirsutism in women, most commonly caused by polycystic ovary syndrome, should be evaluated with tools like the Ferriman–Gallwey score and total testosterone measurements, and managed using methods like hair removal and combined oral contraceptives when fertility preservation is not a priority.

This study found that supplementing myo-inositol with microlipodispersed magnesium significantly improved acne and hirsutism in women with PCOS by reducing BMI, testosterone, and DHEAS levels, also enhancing quality of life without side effects, over 6 months.

In this study of infertile Indonesian women with PCOS, researchers found no correlation between hirsutism, body measurements, and sexual dysfunction scores, but noted that hirsutism may be linked to higher anxiety levels.

This study found that oral contraceptive pills containing cyproterone acetate and drospirenone were more effective at reducing hirsutism in women with PCOS than those containing levonorgestrel over a 6-month period.